Kymera Therapeutics (KYMR) Expected to Announce Quarterly Earnings on Thursday

Kymera Therapeutics (NASDAQ:KYMR) is anticipated to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Kymera Therapeutics to post earnings of ($0.78) per share and revenue of $14.8030 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock opened at $88.43 on Tuesday. The firm has a market capitalization of $6.36 billion, a P/E ratio of -24.63 and a beta of 2.21. Kymera Therapeutics has a one year low of $19.44 and a one year high of $103.00. The business has a fifty day moving average price of $77.76 and a 200-day moving average price of $64.14.

Analyst Upgrades and Downgrades

KYMR has been the subject of several analyst reports. JPMorgan Chase & Co. raised their target price on Kymera Therapeutics from $70.00 to $125.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. Piper Sandler reaffirmed an “overweight” rating and set a $125.00 price objective (up previously from $98.00) on shares of Kymera Therapeutics in a research note on Tuesday, December 9th. Leerink Partners upped their target price on shares of Kymera Therapeutics from $70.00 to $118.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Wells Fargo & Company raised their price target on shares of Kymera Therapeutics from $69.00 to $116.00 and gave the company an “overweight” rating in a report on Tuesday, December 9th. Finally, BTIG Research restated a “buy” rating and set a $138.00 price target on shares of Kymera Therapeutics in a research report on Tuesday, February 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Kymera Therapeutics currently has an average rating of “Buy” and a consensus price target of $117.00.

Insider Activity

In related news, Director Bros. Advisors Lp Baker acquired 2,005,813 shares of the company’s stock in a transaction dated Thursday, December 11th. The stock was bought at an average cost of $86.00 per share, with a total value of $172,499,918.00. Following the acquisition, the director owned 7,955,916 shares of the company’s stock, valued at approximately $684,208,776. The trade was a 33.71% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction on Monday, December 8th. The shares were sold at an average price of $89.76, for a total value of $448,800.00. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 420,895 shares of company stock worth $37,778,351. Corporate insiders own 16.01% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

A number of large investors have recently modified their holdings of the company. Orion Porfolio Solutions LLC bought a new position in Kymera Therapeutics during the 4th quarter worth approximately $223,000. Hudson Bay Capital Management LP purchased a new stake in shares of Kymera Therapeutics during the second quarter valued at approximately $218,000. BNP Paribas Financial Markets grew its holdings in shares of Kymera Therapeutics by 45.8% in the second quarter. BNP Paribas Financial Markets now owns 4,982 shares of the company’s stock worth $217,000 after purchasing an additional 1,565 shares during the last quarter. Oxford Asset Management LLP bought a new position in shares of Kymera Therapeutics in the second quarter worth approximately $201,000. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Kymera Therapeutics in the fourth quarter worth $153,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.